Advertisement
Advertisement

SLNO

SLNO logo

Soleno Therapeutics, Inc. Common Stock

41.54
USD
Sponsored
+1.96
+4.95%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

41.50

-0.04
-0.10%

SLNO Earnings Reports

Positive Surprise Ratio

SLNO beat 21 of 39 last estimates.

54%

Next Report

Date of Next Report
Feb 25, 2026
Estimate for Q4 25 (Revenue/ EPS)
$89.58M
/
$0.71
Implied change from Q3 25 (Revenue/ EPS)
+35.69%
/
+51.06%
Implied change from Q4 24 (Revenue/ EPS)
--
/
-155.91%

Soleno Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 04, 2025, SLNO reported earnings of 0.47 USD per share (EPS) for Q3 25, beating the estimate of 0.05 USD, resulting in a 759.23% surprise. Revenue reached 66.02 million, compared to an expected 49.06 million, with a 34.58% difference. The market reacted with a -26.59% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 15 analysts forecast an EPS of 0.71 USD, with revenue projected to reach 89.58 million USD, implying an increase of 51.06% EPS, and increase of 35.69% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Soleno Therapeutics, Inc. Common Stock reported EPS of $0.47, beating estimates by 759.23%, and revenue of $66.02M, 34.58% above expectations.
The stock price moved down -26.59%, changed from $63.85 before the earnings release to $46.87 the day after.
The next earning report is scheduled for Feb 25, 2026.
Based on 15 analysts, Soleno Therapeutics, Inc. Common Stock is expected to report EPS of $0.71 and revenue of $89.58M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement